Recently, the world-renowned business magazine Fortune released the "2026 China Environmental, Social, and Governance (ESG) Impact List". Sino Biopharmaceutical (1177.HK) was selected for the list for the first time due to its outstanding practices in green and low-carbon initiatives, social value creation, and corporate governance. This marks another breakthrough for the company in the field of international key ESG impact assessments, continuously demonstrating its responsibility and commitment in the area of international sustainable development. 

Fortune pointed out that in 2026, a year intertwined with geopolitical rifts and digital revolution, good ESG practices are a company's "immune system" for withstanding shocks and maintaining resilience. This year's list focuses on robust companies that maintain resilience amidst turmoil through green technology, concern for people, and good governance, aiming to provide replicable examples for the entire business world in facing this sustainability stress test. 

Sino Biopharmaceutical is committed to enhancing operational resilience through good ESG practices, thereby more calmly embracing the opportunities and challenges brought by international development. We continuously promote the integration of low-carbon models with the entire product lifecycle and responsibly embed AI applications deeply into our full industry chain operations, delivering a high-quality sustainable development report card through sound practices. 

As the global energy transition deepens and climate change challenges become more severe, Sino Biopharmaceutical has taken the lead in the pharmaceutical industry by releasing its own carbon neutrality goals and implementation pathway. It has published a Phase I (2025-2030) implementation plan focusing on five core areas: "improving mechanisms, optimizing energy structure, saving energy and reducing carbon in production and operations, building a low-carbon supply chain, and fostering a low-carbon culture."In 2025, Sino Biopharmaceutical achieved a simultaneous decrease in both total carbon emissions and intensity for the first time. The use of renewable energy increased by over 500% year-on-year, which not only advances the carbon neutrality goal but also effectively hedges against the risks of energy price fluctuations. 

Against the backdrop of AI completely reshaping the industrial landscape, Sino Biopharmaceutical adheres to a discerning approach in embracing AI. It deeply integrates AI technology into the entire chain of drug R&D, intelligent manufacturing, and quality control, achieving significant reductions in R&D cycles, optimizing production process systems, and enhancing drug quality and supply efficiency to protect patient health with higher-quality, more accessible innovative drugs. 

At the same time, the company places great importance on the risks brought by AI, including changes in employment structure, data security, and algorithmic ethics. We have established a full-process AI governance and risk control system, adhering to the employment philosophy of "empowerment, not replacement." We conduct company-wide digital and AI skills training to help employees reskill. We strictly follow the principle of data minimization, strengthen algorithmic interpretability and privacy protection, and build a closed loop of ethical review and security control. This achieves a balanced development between technological innovation, social stability, and public trust, promoting AI for good and ensuring its steady and long-term progress.

The Fortune China ESG Impact List is one of the most prestigious benchmark lists in China's ESG field. As of 2026, it has been published for 5 consecutive years. This year's list attracted applications from over 300 leading companies, with a total of 100 companies selected, covering various sectors such as new energy, technology, finance, manufacturing, consumer goods, logistics, and pharmaceuticals. The list's selection process not only focuses on the construction of a company's ESG system but also emphasizes its groundbreaking practical contributions to core ESG issues relevant to its industry, and whether the company has integrated ESG concepts into its long-term strategy. The aim is to select leading enterprises that have a positive impact on the sustainable development of China's business environment. 

Sino Biopharmaceutical insists on integrating the ESG concept into every aspect of its corporate operations. Through high-quality ESG management, we earnestly practice our mission to "improve the quality of life and uphold the dignity of life", striving for the health and well-being of more patients and contributing to the sustainable development of the industry and the nation.